skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

Review

(836) Views  (264) Full article downloads

Authors: Deshpande H, Marler V, Sosa JA

Published Date December 2011 Volume 2011:4 Pages 209 - 215
DOI: http://dx.doi.org/10.2147/OTT.S17422

Hari Deshpande1,3, Vicky Marler3, Julie Ann Sosa2,3
1Department of Medicine, 2Department of Surgery, Yale University School of Medicine, 3Yale Cancer Center, New Haven, CT, USA

Abstract: Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because it is an orally bioavailable medication that targets the growth factors felt to be important in the pathogenesis of this disease, ie, the rearranged during transfection proto-oncogene and vascular endothelial growth factor receptor. It was tested initially in two Phase II studies at doses of 100 mg and 300 mg daily. Although activity was seen at both doses, the higher dose was chosen for a randomized, placebo-controlled Phase II study. This trial, which accrued more than 300 patients, showed a statistically significant benefit for the group taking vandetanib compared with those taking placebo medication. Progression-free survival for the vandetanib arm has not been reached, compared with 19 months for the placebo arm. The main toxicity appears to be diarrhea, although some patients experienced significant side effects, including torsades de pointes and sudden cardiac death. Therefore, it is now necessary for practitioners to enroll in a Risk Evaluation Mitigation Strategy before being allowed to prescribe this medication, to reduce the risk of serious side effects occurring.

Keywords: ZD6474, medullary thyroid cancer, vandetanib





 

Other articles by Dr Hari Deshpande



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Sorafenib in metastatic MTC – a case report and minireview of the literature
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
Current therapeutic strategies for invasive and metastatic bladder cancer
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
In vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsions
Targeted agents for the treatment of metastatic melanoma
Role of vandetanib in the management of medullary thyroid cancer
Hedgehog pathway as a drug target: Smoothened inhibitors in development
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer